Mentioned 8/31/2026
Boston Scientific is a top research priority due to a potential mismatch between its price and expected growth, trading near 52-week lows after a significant year-to-date decline, with strong buy ratings from analysts, though a recent cybersecurity incident introduces uncertainty.
Analysis from 8/31/2026